Kornimate/medical-research-clean huggingface dataset:
onabotulinumtoxin a versus kenalog for chronic pelvic pain

Conditions: Pelvic Pain

Summary: the goal of this study is to compare the effectiveness of two different medications used in intravaginal trigger point injections (injections into extremely painful areas of a muscle) to treat chronic pelvic pain. the study compares onabotulinumtoxina (botox®) (a drug prepared from the bacterial toxin botulin which temporarily paralyzes muscles) to kenalog (a synthetic corticosteroid used as an anti-inflammatory agent).

chronic pelvic pain (cpp) is a common and often debilitating problem among women. the musculoskeletal system is an important factor in chronic pelvic pain. studies have demonstrated that women with cpp had more frequent musculoskeletal findings. on physical examination, myofascial trigger points have been found. trigger points are hyperirritable bands of muscle that can be felt from the vaginal wall. they are often knot-like or taut and are painful when pressure is placed on them. intravaginal injections of these trigger points using steroids including kenalog (triamcinolone) have been done and produced decreases in pelvic pain. trigger point injections of onabotulinumtoxin a has also been shown to decrease pain in subjects with cpp. this study will compare these two drugs and assess pain (using subject questionnaires) at one, three and six months post injection.

Eligibility criteria:
inclusion criteria: * provide informed consent * healthy women \> age 18 regardless of menopausal status * willing and able to fill out study questionnaires. in patients that are unable to read, the research nurse will be available to assist. * high-tone pelvic floor dysfunction on vaginal exam * a pelvic pain score of \> 4 on screening visual analog scale (vas) * pain perceived to be in the pelvis that has been present for at least 3 months. exclusion criteria: * patients that have had botox to the bladder within the last 8 months * patients that have had botox outside the bladder of \> 160 u within the last 12 weeks. * patients that have had transvaginal trigger point injections of any form (botox or steroid) in the last 3 months * pregnancy * concomitant use of any narcotic drug, alcohol, or any illicit drug use during the study period that could be deemed unsafe in combination with study medication as judged by the investigators. * any evidence of vaginitis on wet mount slide at initial visit that is untreated. * subject with any other vaginal epithelial disorder that could affect absorption of medication as deemed by the investigators. * any indication/condition/medication that the investigators identify as contraindicated in conjunction with study medication. * systolic blood pressure \> 160 mm hg on screening blood pressure * heart rate \> 110 beats/minute on screening heart rate
effects of rosiglitazone (extended release tablets) on cerebral glucose utilisation and cognition alzheimers disease

Conditions: Alzheimer's Disease

Summary: clinical features in patients with the familial early onset forms and the sporadic forms of alzheimers disease are similar, although the course of deterioration may be different. it would be very informative to examine the drug response of patients with alzheimers disease by a certain genotype to find evidence favouring genotype-specific drug responses that may indicate genetically defined phenotypic differences in alzheimers disease.


Eligibility criteria:
inclusion criteria: * meets the national institute of neurological and communicative diseases and stroke/alzheimers disease and related disorders association (nincds-adrda) criteria for alzheimers disease, regardless of date of diagnosis relative to study entry date. * has an alzheimers disease status of mild to moderate, as classified by a mini mental state examination (mmse) score of 16 - 26 inclusive at screening. * post-menopausal females defined as menopause is defined as \>6 months without menstrual period with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. however if indicated this should be confirmed by oestradiol and fsh levels consistent with menopause (according to local laboratory ranges). * women who are on hrt (hormone replacement therapy) treatment, and have not been confirmed as post-menopausal should be advised to use contraception. * has a permanent caregiver who is willing to attend all visits, oversee the subjects compliance with protocol-specified procedures and study medication, and report on subjects status. (subjects living alone or in a nursing home are not eligible). exclusion criteria: * has a history of or suffers from claustrophobia. * is unable to lie comfortably on a bed inside a pet camera with their head in the field of view for at least 60 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis). * has a history or presence of other neurological or other medical conditions that may influence the outcome or analysis of the pet scan results. examples of such conditions include, but are not limited to stroke, traumatic brain injury, epilepsy or space occupying lesions. * history of type i or type ii diabetes mellitus. * fasting plasma glucose level \>126 mg/dl (\>7.0 mmol/l) or hba1c \>6.2%. * history or clinical/laboratory evidence of moderate congestive heart failure defined by the new york heart association criteria (class ii-iv.

Keywords: avandia alzheimers disease
french validation of the memorial anxiety scale for patients with prostate cancer.

Conditions: Prostate Cancer

Summary: a specific scale allowing the measure of anxiety of patients with protate cancer has been designed and validated but the french version needs to be validated. this study aims at validating the french translation of this scale.

the psychological difficulties encountered by patients with prostate cancer are widely known. there are, however, problems in the identification of certain disorders that require appropriate psychological management. in order to diagnose patients with anxiety more finely, a prostate cancer-specific anxiety measurement scale (max-pc) was developed and validated. this scale includes three sub-dimensions: anxiety related to prostate cancer, anxiety related to the psa assessment and fear of recurrence. this scale generally has good psychometric properties which are found in different populations and in different countries. the dimensions of the max-pc correlate with other anxiety measurement scales such as beck or hads, but do not show redundancy: it captures a specific anxiety related to the experience of patients with prostate cancer. to date, this sclae is not validated in french, and its use in the frame of clinical trials or in routine practice require a first validation.

Eligibility criteria:
inclusion criteria: * patients with prostate cancer diagnosed within 12 months exclusion criteria: n/a
an observational registry of abatacept in patients with juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis

Summary: the purpose of this study is to examine the long-term safety of abatacept for the treatment of juvenile idiopathic arthritis (jia) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * diagnosis of jia (any subtype) * age \< 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept * receiving abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial * parent or legally acceptable representative willing to participate in the study and sign the informed consent exclusion criteria: * pregnant or nursing female at the time of enrollment * prior malignancies if the patient has not been malignancy free for at least 5 years. * any serious acute or chronic medical condition other than jia, including chronic infection, which would compromise the patient's ability to participate in the study * known poor compliance with clinic visits (based on physician judgment)
home ventilatory support in children

Conditions: Sleep Apnea Syndromes in Children

Summary: the study consist of children, who have used home ventilatory support during years 2010-2020 in tampere university hospital. the study will describe retrospectively different diagnoses and symptoms which will lead to home ventilatory support. we also study compliance to treatment and it's disanvantages. the prospective part of the study describes the quality of live of these children by using questionnaires (pedsql).


Eligibility criteria:
inclusion criteria: - icd-10 code for sleep apnea diagnose g47.3 and g47.3 diagnose found from pediatric electronic patient records between years 2010-2020 or patient name found from pediatric multidisciplinary home respiratory team's clinical list exclusion criteria: * age over 16 * patient starting home ventilation after 31st december 2020 or treatment ending before 1st january 2010 * patients with sleep apnea but without home respiratory support treatment * only theophylline treatment * high-flow oxygen therapy * age over 16 at treatment onset * never started treatment * treatment starting point and ending before year 2010
abbreviated breast mri (ab-mri) with golden-angle radial compressed-sensing and parallel imaging (grasp)

Conditions: Breast Cancer

Summary: the purpose of this study is to use a magnetic resonance imaging (mri) sequence called golden-angle radial compressed sensing and parallel imaging (grasp) as a noninvasive and fast way to measure the wash-in contrast (dye) in the breast. mri uses a strong magnetic field and radio waves to create images of structures in the body. the goal is to determine if benign and malignant breast lesions have different patterns of contrast wash in. this study will ask woman planning to undergo a clinical breast mri with contrast (dye) as part of their standard care.


Eligibility criteria:
inclusion criteria: * no contraindications to mri scanning (pacemaker, implanted metallic objects, severe obesity or other condition that leads to difficulty lying in the magnet) * able and willing to provide informed consent exclusion criteria: * currently undergoing neoadjuvant chemotherapy for breast cancer treatment.
the impact of dietary treatment in patients with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the obtained results are likely to determine whether changes in the diet of patients with irritable bowel syndrome will affect their nutritional status. they will also allow you to assess whether dietary treatment will affect the resolution or alleviation, or severity of disease symptoms in ibs. the test results can be used in clinical practice. participation in the study does not carry any risk of complications associated with undergoing a medical experiment.

this is a randomized, parallel study that includes 1 initial visit and 1 final visit, separated by 8 weeks of diet. the investigators enrolled 73 women in the study, who met the criteria for inclusion in the study, to determine whether changes in the diet of patients with irritable bowel syndrome will affect their nutritional status. at the initial and final visit (after 8 weeks) in all patients, anthropometric measurements, body composition, an interview questionnaire concerning the symptoms of the disease was performed, the intensity of abdominal pain was assessed, the life quality of patients on the ibs-qol scale was assessed, the calprotectin concentration in the stool was determined and the questionnaire regarding the quantitative assessment of diet was performed. the study population was divided using simple lottery into 3 groups with different dietary treatment for 8 weeks: group 1 - 26 patients - diet with low content of easily fermenting carbohydrates (fodmap), group 2 - 21 patients - an elimination-rotation diet, and group 3 - (control) - 26 patients - classic diet treatment (recommended by the leading gastroenterologist).

Eligibility criteria:
inclusion criteria: 1. patients with irritable bowel syndrome (mixed) according to rome iii criteria, in whom the gastroenterologist does not find any other gastrointestinal diseases that may affect this study 2. patients who understand the purpose and nature of the study, agree to its terms and give informed written consent before entering the study 3. who are physically and mentally able to participate in the study and express their will to cooperate exclusion criteria: 1. patients who use strong opioid and psychotropic drugs: barbiturates 2. patients who take part in another clinical trial related to the treatment of gastrointestinal diseases or dietary therapy within 90 days prior to inclusion in this study 3. patients who have a pacemaker or heart defibrillator implanted and metal endoprostheses (due to the used body composition test method (bia - bioelectrical impedance analysis)

Keywords: irritable bowel syndrome diet
measurement of vanilloïd compounds in urin of autistic vs control patients, as potential biomarkers

Conditions: Autism Spectrum Disorder

Summary: in a former study, four vanilloid compounds were observed increased in the urin of autistic patients. the present study is aimed at performing a ambispective study to confirm or not these preliminary results. 70 urins from autistic children (already collected) will be compared to 70 urins of non autistic children (collected without intervention, remaining sample from the standard care), in terms of measurements of four vanilloid compounds using a gcms apparatus.


Eligibility criteria:
inclusion criteria : for cases : * male children aged 2 years to less than 15 years inclusive years at time of sample collection * children with a diagnosis of autism (icd-10 f84.0) after assessment by a child psychiatrist. for healthy chlidren: * children aged 2 years to less than 15 years old performing an ecbu at the chru of nancy as part of their care. * patient whose ecbu is negative with respect to cytobacteriology (absence of urinary infection). * child can be matched to a cas exclusion criteria for cases: * children in whom one of the following pathologies is found during the anamnesis or in the clinical record : (i) renal insufficiency; (ii) urinary tract infection at the time of sampling and/or metabolic disease * children on antibiotic treatment at the time of collection for healthy chlidren : * children whose urine culture come from one of the following departments: pediatric nephrology (potential risk of renal failure) or pediatric neurology (potential risk of neurological disorder). * with a diagnosis of autism * with a metabolic disease * children undergoing antibiotic treatment at the time of collectio
mivacunala: an intervention to improve covid-19 vaccination behaviors among latinos

Conditions: COVID-19 Pandemic

Summary: the aim of this study is to determine whether a community-informed, linguistically and culturally tailored educational program delivered via mobile phone is effective in improving vaccination behaviors among latino families. thus we evaluate a community-based mobile phone intervention (mivacunala) to assess if there is an increase in vaccination rates among 12-17 year old children and willingness to vaccinate 2-11year old children who have not been previously vaccinated who reside in high-risk and low resourced neighborhoods in los angeles.

we conducted a community-based randomized clinical trial with a wait list control group among adult latino parents or caregivers in east and south los angeles. participants completed an online demographic and baseline survey and were randomly assigned to treatment or wait-list control. based on their preference, participants received a weekly text message or email link twice a week for four weeks (mon and wed at noon). twice a week messages consisted of a short text (\<160 characters) linking participants to a 2-3 minute video (monday) and educational text (around 500 words in length. the material was divided into weekly topics regarding the coronavirus vaccine and other topics relevant to the latino community. participants were also directed to reliable websites where they could access additional information and links with instructions on where to get vaccinated. upon completing the intervention, participants completed a 1-month follow-up survey.

Eligibility criteria:
inclusion criteria: 1. self-identified as latino/a, 2. were 18 years or older, 3. had at least one unvaccinated child of any age (17 or younger), and 4. had the means to receive messages and review educational material online, such as a text-capable mobile phone with internet access exclusion criteria: 1. unable to receive information via mobile text or computer. 2. does not speak english or spanish.

Keywords: vaccination, vulnerable populations, health disparities
glucagon in the treatment of hypoglycemia in newborn infants of diabetic mothers

Conditions: Hypoglycemia

Summary: thesis infants of diabetic mothers are at high risk to develop hypoglycemia after birth. after birth, glucose and ketone bodies are the main substrates of brain energy. under normal condition, the adrenergic response seen immediately after birth suppresses insulin release and stimulates glucagon secretion which enhances gluconeogenesis and ketogenesis. an inversion of the insulin/glucagon ratio is seen soon after birth as a normal, physiologic phenomenon. consequently, a post delivery glucose nadir is reached between 30 to 90 minutes after birth, followed by a spontaneous recovery before 3-4 hours of age. in infants of diabetic mothers, this inversion of the ratio is postponed and a more profound and sustained hypoglycemia is seen. early feeding is of great importance to diminish the severity and incidence of hypoglycemia. but, if despite an appropriate calorie intake, low levels of sugar are seen, an intravenous infusion of glucose should be commenced. in case that iv glucose is not effective or can't be supplied immediately, intramuscular glucagon is a therapeutic alternative. we hypothesize that a single intramuscular injection of glucagon together with the appropriate oral intake of nutrients is a safe and an effective alternative to the iv infusion of glucose alone in the treatment of hypoglycemia in term infants of diabetic mothers. methods appropriately grown or large for date, term infants of insulin treated diabetic mothers, with no other known medical problems, are potential candidates for our study. hypoglycemia will be defined as serum glucose level lower than 45 mg%. infants of diabetic mothers will arrive to the nursery and immediately receive early feeding before 30 minutes of life. at that time, glucose will be checked. if glucose level is lower than 45 mg%, treatment with iv glucose or im glucagon will be initiated. glucose will be checked every hour for 4 hours and then every 3 hours (before each meal) for the next 20 hours. in case blood glucose level is lower than 20 mg% or falls below 45 mg% despite glucagon treatment, iv glucose will immediately be instituted. our aim is to check that im glucagon is as good as iv glucose in the treatment of hypoglycemia in infants of diabetic mothers. we will compare glucose levels after treatment with iv glucose and im glucagon, the time till normalization of glucose and full feeding is achieved and the number of hospitalization days in both groups.


Eligibility criteria:
inclusion criteria: * asymptomatic hypoglycemia * infant of insulin treated diabetic mother * aga or lga * no other known medical problems exclusion criteria: * concurrent medical problems * symptomatic hypoglycemia * glucose under 20 mg%

Keywords: hypoglycemia glucagon neonatal gestational diabetes insulin glyburide
a safety and efficacy study of a new eye drop formulation in patients with dry eye disease.

Conditions: Dry Eye Syndromes

Summary: this study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.


Eligibility criteria:
inclusion criteria: * used artificial tears for dry eye * visual acuity of at least 20/32 (while wearing glasses, if necessary). exclusion criteria: * use of contact lenses in the last 3 months, or anticipated use of contact lenses during the study * herpes keratitis in the last 6 months * cataract surgery, laser-assisted in situ keratomileusis \[lasik\], or photorefractive keratectomy, within the last 6 months
a study of cabiralzumab given by itself or with nivolumab in advanced cancer or cancer that has spread

Conditions: Advanced Malignancies

Summary: the purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, is safe and tolerable in the treatment of advanced malignancies.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * performance status 0-1 * adequate organ function * cohort m1, 2 and c1: measurable disease * cohort m1, m2 and c1: subjects must have histologic or cytologic confirmation of an advanced (metastatic and/or unresectable) malignant solid tumor * cohort c2: documented refractory or relapsed multiple myeloma * subjects must be refractory to or have relapsed after standard therapies, or have no known effective treatment exclusion criteria: * cohort m1, m2, and c1: untreated or active central nervous system (cns) or leptomeningeal metastases * cohort m1, m2, and c1: subjects with hepatocellular carcinoma (hcc) * cohort c2: subjects with solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia other protocol defined inclusion/exclusion criteria could apply